Tags

Type your tag names separated by a space and hit enter

Differences in outcomes between cholecalciferol and ergocalciferol supplementation in veterans with inflammatory bowel disease.
Geriatr Gerontol Int. 2012 Jul; 12(3):475-80.GG

Abstract

AIM

Vitamin D deficiency is a global health issue associated with increased health-care costs, and could play a role in the pathogenesis and management of inflammatory bowel disease. Prior studies show a high prevalence of vitamin D deficiency in veterans with inflammatory bowel disease. We aimed to examine the outcome differences in patients with inflammatory bowel disease, comparing treatment with ergocalciferol to cholecalciferol.

METHODS

A retrospective review of electronic medical records of patients with inflammatory bowel disease at a Veterans Affairs Medical Facility in the Southeastern United States was carried out. Those with at least one serum 25(OH) vitamin D level were included. Initial and follow-up vitamin D values were recorded. The type of vitamin D supplementation, whether cholecalciferol or ergocalciferol, was documented. Costs in the year after measurement of vitamin D were divided into separate inpatient and outpatient categories.

RESULTS

Veterans (n = 108) with ulcerative colitis or Crohn's disease and an available 25(OH) vitamin D level were studied. There were differences in follow-up vitamin D levels; those who received weekly ergocalciferol had higher subsequent levels than those who received cholecalciferol, especially at a second follow up, although differences did not achieve statistical significance. However, those who received vitamin D3 were less likely to use laboratory, pharmacy, radiology and fee-based services, and had lower laboratory and pharmacy costs.

CONCLUSIONS

Our data suggest that cholecalciferol replacement might improve outcomes to a greater extent than ergocalciferol, and might be better in limiting health-care costs and expenses in patients with inflammatory bowel disease.

Authors+Show Affiliations

Department of Internal Medicine, Division of Infectious Diseases, East Tennessee State University, Johnson City, Tennessee, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

22233182

Citation

Youssef, Dima, et al. "Differences in Outcomes Between Cholecalciferol and Ergocalciferol Supplementation in Veterans With Inflammatory Bowel Disease." Geriatrics & Gerontology International, vol. 12, no. 3, 2012, pp. 475-80.
Youssef D, Bailey B, Atia A, et al. Differences in outcomes between cholecalciferol and ergocalciferol supplementation in veterans with inflammatory bowel disease. Geriatr Gerontol Int. 2012;12(3):475-80.
Youssef, D., Bailey, B., Atia, A., El-Abbassi, A., Manning, T., & Peiris, A. N. (2012). Differences in outcomes between cholecalciferol and ergocalciferol supplementation in veterans with inflammatory bowel disease. Geriatrics & Gerontology International, 12(3), 475-80. https://doi.org/10.1111/j.1447-0594.2011.00798.x
Youssef D, et al. Differences in Outcomes Between Cholecalciferol and Ergocalciferol Supplementation in Veterans With Inflammatory Bowel Disease. Geriatr Gerontol Int. 2012;12(3):475-80. PubMed PMID: 22233182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differences in outcomes between cholecalciferol and ergocalciferol supplementation in veterans with inflammatory bowel disease. AU - Youssef,Dima, AU - Bailey,Beth, AU - Atia,Antwan, AU - El-Abbassi,Adel, AU - Manning,Todd, AU - Peiris,Alan N, Y1 - 2012/01/10/ PY - 2012/1/12/entrez PY - 2012/1/12/pubmed PY - 2012/12/10/medline SP - 475 EP - 80 JF - Geriatrics & gerontology international JO - Geriatr Gerontol Int VL - 12 IS - 3 N2 - AIM: Vitamin D deficiency is a global health issue associated with increased health-care costs, and could play a role in the pathogenesis and management of inflammatory bowel disease. Prior studies show a high prevalence of vitamin D deficiency in veterans with inflammatory bowel disease. We aimed to examine the outcome differences in patients with inflammatory bowel disease, comparing treatment with ergocalciferol to cholecalciferol. METHODS: A retrospective review of electronic medical records of patients with inflammatory bowel disease at a Veterans Affairs Medical Facility in the Southeastern United States was carried out. Those with at least one serum 25(OH) vitamin D level were included. Initial and follow-up vitamin D values were recorded. The type of vitamin D supplementation, whether cholecalciferol or ergocalciferol, was documented. Costs in the year after measurement of vitamin D were divided into separate inpatient and outpatient categories. RESULTS: Veterans (n = 108) with ulcerative colitis or Crohn's disease and an available 25(OH) vitamin D level were studied. There were differences in follow-up vitamin D levels; those who received weekly ergocalciferol had higher subsequent levels than those who received cholecalciferol, especially at a second follow up, although differences did not achieve statistical significance. However, those who received vitamin D3 were less likely to use laboratory, pharmacy, radiology and fee-based services, and had lower laboratory and pharmacy costs. CONCLUSIONS: Our data suggest that cholecalciferol replacement might improve outcomes to a greater extent than ergocalciferol, and might be better in limiting health-care costs and expenses in patients with inflammatory bowel disease. SN - 1447-0594 UR - https://www.unboundmedicine.com/medline/citation/22233182/Differences_in_outcomes_between_cholecalciferol_and_ergocalciferol_supplementation_in_veterans_with_inflammatory_bowel_disease_ L2 - https://doi.org/10.1111/j.1447-0594.2011.00798.x DB - PRIME DP - Unbound Medicine ER -